About FSHD Canada Foundation
Funded Research

Optimizing Gapmer Therapy for Facioscapulohumeral Muscular Dystrophy

Principle Investigator: Yi-Wen Chen Research Institution: George Washington School of Medicine Antisense oligonucleotide (AON) therapy is a promising approach to treating FSHD. However, several issues arise with AONs including: difficulty…

Read More

In vivo model to validate drugs targeting DUX4 enhancer/promoter activity

Principle Investigator: Yosuke Hiramuki (at Peter Jone’s laboratory) Research Institution: University of Nevada DUX4 is normally expressed in testis in healthy individuals and aberrantly expressed in specific skeletal muscles of…

Read More

Pre-clinical testing for FSHD CRISPR-inhibition therapy

Principle Investigator: Associate Professor Peter Jones Research Institution: University of Nevada CRISPR technology provides an avenue for targeting and correcting virtually any sequence in the human genome, with long-term or…

Read More

Facio Therapies

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…

Read More

Development of next-generation AAV vectors for effective CRISPR inhibition of FSHD

Investigator: Charis L. Himeda, PhD, Research Assistant Professor, University of Nevada, Reno School of Medicine, Reno NV USA CRISPR technology provides an avenue for specifically targeting and manipulating virtually any…

Read More

Identify Biomarkers for FSHD Using Omics Approaches

Investigator: Yi-Wen Chen, Ph.D. (Children’s Research Institute in Silver Spring, Maryland) Biomarkers are biological changes that can be used as indicators of physiological and disease states. Biomarkers can be valuable…

Read More
https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca